Stock analysis for Wilson Therapeutics AB (WTX) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

2018-06-15

På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Wilson Therapeutics AB – Org.nummer: 556893-0357. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m.

Hitta adress på karta, kontaktinfo, nyckeltal och befattningar. Wilson Therapeutics AB 556893-0357 (Stockholm) Översikt Telefonnummer Adresser Styrelse och koncern Verklig huvudman Nyckeltal Kreditupplysning Wilson Therapeutics AB is a Sweden-based biopharmaceutical company that is active in the development of a treatment for Wilson disease. Wilson disease is a genetic disease that causes copper poisoning. NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Wilson Therapeutics AB (publ) announced today that Alexion has made a recommended public cash offer to the Enligt beslut av Nasdaq Stockholm kommer Wilson Therapeutics AB (publ) att avnoteras från Nasdaq Stockholm. Sista dag för handel i aktien blir den 15 juni 2018. Om Wilson TherapeuticsWilson Therapeutics är ett bioteknikbolag, baserat i Stockholm, som utvecklar nya läkemedel för patienter med ovanliga kopparrelaterade sjukdomar.

Wilson Therapeutics AB (publ) Delårsrapport 1 januari – 31 mars 2017 Förberedelser inför fas 3 löper enligt plan 1 januari – 31 mars 2017 · Nettoomsättningen uppgick till 0,0 (0,0) MSEK · Periodens resultat uppgick till -31,4 (-22,3) MSEK · Resultatet per aktie före/efter utspädning uppgick till -1,22 (-17,62) SEK · Likvida medel per den 31 mars uppgick till 339,3 (53,0) MSEK This page provides a brief financial summary of Wilson Therapeutics AB as well as the most significant critical numbers from each of its financial reports. Wilson Therapeutics AB (publ) tillkännager att bolagets pågående fas II-studie som utvärderar effekt och biverkningsprofilen för Decuprate® (kolintetrathiomolybdat; WTX101) i patienter med Get instant access to a free live streaming chart of the Wilson Therapeutics AB Stock. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area, lines WILSON THERAPEUTICS AB : Financial news and information Stock WILSON THERAPEUTICS AB | Nasdaq Stockholm: WTX | Nasdaq Stockholm Wilson Therapeutics AB Kungsgatan 3 | 111 43 Stockholm | Sweden +46 8 796 00 00 www.wilsontherapeutics.com 1 • • • • • • • • • • • • • • • Jonas Hansson, CEO of Wilson Therapeutics Amounts in SEK 000s Jul–Sep Jan–Sep Jan–Dec 2017 2016 2017 2016 2016 1) Adjusted for share split 1:10 resolved in April 2016.

Wilson Therapeutics AB Kungsgatan 3 | 111 43 Stockholm | Sweden +46 8 796 00 00 www.wilsontherapeutics.com 1 • • • • • • • • • • • • • • • Jonas Hansson, CEO of Wilson Therapeutics Amounts in SEK 000s Jul–Sep Jan–Sep Jan–Dec 2017 2016 2017 2016 2016 1) Adjusted for share split 1:10 resolved in April 2016.

Wilson Therapeutics AB (publ) is a drug development company, that develops novel therapies for patients with rare diseases such as Wilson Disease. Patients with Wilson Disease suffer from an overload of copper in the liver, brain and other tissues resulting in organ damage and dysfunction. It is universally fatal if left undiagnosed and untreated.

11 apr 2018 Alexions bud har fått Wilson Therapeutics aktie att rusa på börsen. Men det finns utrymme för högre bud. ”Under vissa omständigheter kommer

Wilson Therapeutics huvudprodukt WTX101 utvecklas primärt Budpremien är 70 procent jämfört med stängningskursen för Wilson Therapeutics-aktien om 136 kronor den 10 april, vilket alltså är den sista handelsdagen före offentliggörandet av budet.

Juridiskt namn. Wilson Therapeutics AB. F-skatt. Ja, registrerad för F-skatt. Org. nummer. 556893-0357. Datum för upprättande. 2012-05-11.
Oheliga allianser

556893-0357 Wilson Therapeutics AB: Instrument: SE0008293674 Ordinary Shares: Innehavare: Polar Capital LLP Före transaktionen: Antal aktier: 587 177: Antal rösträtter: 587 177 Transaktionen: Skäl för flaggning: Övrigt: Datum: 2017-12-12: Gränsvärde för antal aktier: 5 %: Gränsvärde för rösträtter: 5 % Efter transaktionen: Antal Publication date Issuer Person discharging managerial responsibilities Position Closely associated Nature of transaction Instrument name ISIN Transaction date Sep 14, 2012 Wilson Therapeutics AB (“Wilson”) has acquired Decuprate™ from Tactic Pharma LLC. Wilson Therapeutics is a newly established company Jun 1, 2018 Wilson Therapeutics AB (publ) has requested a delisting of the company's shares from Nasdaq Stockholm.

Wilson Therapeutics AB is a Sweden-based biopharmaceutical company that is active in the development of a treatment for Wilson disease. Wilson disease is a genetic disease that causes copper poisoning. Wilson Therapeutics AB (publ), announces that the company’s ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Wilson Therapeutics AB (publ) (“Wilson Therapeutics” or the “Company”), hereby announces the outcome relating to the offering of newly issued shares in the Company (the “Offering”) and listing on Nasdaq Stockholm.
Nordnet index fund

The shareholders of Wilson Therapeutics AB (publ) are summoned to the extraordinary general meeting, to be held on Wednesday 18 January 2017, at 2.00 pm at IVA Conference Center (Rausingrummet), Grev Turegatan 16, Stockholm, Sweden.

Uppköp tillhör inte vanligheterna inom svensk life science, i synnerhet inte i den här storleken. För de institutionella investerare som deltog i Wilsons riktade emission i december till kursen 95 kr, ser detta […] Wilson Therapeutics AB: WTX101 beviljas Fast Track-status av FDA för behandling av Wilsons sjukdom Wilson Therapeutics AB (publ), tillkännager i dag att den amerikanska läkemedelsmyndigheten Food and Drug Administration (FDA) har beviljat WTX101 Fast Track-status för behandling av Wilsons sjukdom. Proff.se ger dig företagsinformation om Wilson Therapeutics AB, 556893-0357.

Wilson Therapeutics AB Report issue. For profit Phase 3. Founded: Stockholm Sweden (2012). Status: Acquired by Alexion (2018) → now AstraZeneca (2020).

Aktiespararna. 5.66K subscribers.

Wilson disease is a genetic disease that causes copper poisoning. to von Emster, investments from that fund that have yielded double-digit returns include exits from Wilson Therapeutics AB..twelfth and leaves it with over $1.2 billion under management. Allison Johnson Abingworth LLP CRISPR Therapeutics AG IFM Therapeutics Inc. Wilson Therapeutics AB Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics (STO:WTX) Wilson Therapeutics AB (publ), announces that the company’s ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline Stockholm, Sweden, where Wilson is based (Thomas Fabian/CC BY-SA 2.0) Alexion has struck an $855 million (€690 million) all-cash deal to acquire Wilson Therapeutics. The takeover will further Wilson Therapeutics AB (publ), today announced that updated preliminary data from the company’s ongoing Phase 2 clinical trial for WTX101 (bis-choline tetrathiomolybdate; Decuprate®) in Wilson Disease will be presented at the Liver Meeting®, organized by the American Association for the Study of Liver Diseases (AASLD), in Boston, Massachusetts, November 11-15.